SCHEMBL6417899

SCHEMBL6417899

COc1cccc(/C=N/Nc2nc3nonc3nc2Nc2cccc(Cl)c2)c1O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 14/20 0.53
KDM4E B2RXH2 10/20 0.53
HTT P42858 8/20 0.53
SMN1; SMN2 Q16637 5/20 0.53
TDP1 Q9NUW8 5/20 0.53
L3MBTL1 Q9Y468 4/20 0.53
KLF5 Q13887 3/20 0.53
PKM P14618 2/20 0.53
NFKB1 P19838 1/20 0.53
NFKB2 Q00653 1/20 0.53
RELA Q04206 1/20 0.53
NPC1 O15118 6/20 0.51
RAB9A P51151 6/20 0.50
LMNA P02545 5/20 0.50
KMT2A Q03164 9/20 0.49
MEN1 O00255 6/20 0.49
HSP90AA1 P07900 1/20 0.49
GAA P10253 4/20 0.49
POLB P06746 6/20 0.46
ALDH1A1 P00352 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6417904 1.00 MAPT (0.53) MAPTKDM4EHTTSMN1; SMN2TDP1
SCHEMBL6431957 0.90 MAPT (0.52) MAPTKDM4EHTTSMN1; SMN2TDP1
SCHEMBL6431965 0.90 MAPT (0.52) MAPTKDM4EHTTSMN1; SMN2TDP1
SCHEMBL6419561 0.89 MAPT (0.53) MAPTKDM4EHTTSMN1; SMN2TDP1
SCHEMBL6416047 0.89 MAPT (0.41) MAPTKDM4EHTTSMN1; SMN2TDP1
SCHEMBL6416048 0.89 MAPT (0.41) MAPTKDM4EHTTSMN1; SMN2TDP1
SCHEMBL6431942 0.89 MAPT (0.51) MAPTKDM4EHTTSMN1; SMN2TDP1
SCHEMBL6431936 0.89 MAPT (0.51) MAPTKDM4EHTTSMN1; SMN2TDP1
SCHEMBL6439515 0.86 MAPT (0.51) MAPTKDM4EHTTSMN1; SMN2TDP1
SCHEMBL6436226 0.86 MAPT (0.51) MAPTKDM4EHTTSMN1; SMN2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
WO-2005044270-A1 OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS 4SC AG (DE) 2005-05-19 WO disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 MAPT 4420/4885KDM4E 3277/4885HTT 3588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.